

AGENDA  
 AREA DRUG AND THERAPEUTICS COMMITTEE  
 MINUTE  
 WEDNESDAY 18<sup>th</sup> JANUARY 2023 @10am  
 Microsoft Teams Meeting

2023/01 1.	<b><u>In Attendance</u></b>	<b><u>Action</u></b>
	<p>Mehrdad Malekian (MM) Chair      Victoria Gemmell (VG) Minutes            Gail Richardson (GR)              David Semple (DS)            John Milne (JM)                      Mark Kirk (MK)            Carol McGoff (CM)                  Emma Harris (EH)            Stephanie Dundas (SD)            Karen Patterson (KP)            Penny Brankin (PB)            Christine Gilmour (CG)</p> <p><b><u>Apologies for Absence</u></b></p> <p>None received</p>	
2023/02 2.	<b><u>Declaration of Interest</u></b>	
	Nil noted	
2023/03 3.	<p><b><u>Matters arising not covered elsewhere on the agenda</u></b></p> <p>a. <b><u>Ratification of minutes of meetings 16<sup>th</sup> November 2023 and 21<sup>st</sup> December 2022</u></b></p> <p>Both sets of minutes were accepted as true records and can now be published</p> <p>b. <b><u>Asthma Treatment Update</u></b> (Trimbow®)</p> <p>Amendments made as previously requested and the protocol was accepted            MM to update author</p> <p>c. <b><u>Dermatology Update</u></b></p> <p>Update awaited            VG to Follow up</p> <p>d. <b><u>Utrogestan Update</u></b></p>	<p></p> <p><b>MM</b></p> <p><b>VG</b></p>

	<p>Update awaited</p> <p>e. <b><u>VTE Treatment Plan update</u></b>          KP discussed with orthopaedic colleagues.          It was noted that the document is not due for review, still current and useful.          The group agreed that it can remain in use but should be updated to remove the word “draft”</p>	<p><b>PB</b></p>
<p>2023/04 4.</p>	<p><b><u>SMC Advice</u></b>  <b><u>FULL SUBMISSIONS</u></b></p> <ul style="list-style-type: none"> <li>• burosumab 10mg, 20mg, 30mg solution for injection (Crysvita) Kyowa Kirin Ltd SMC2514 <b>ULTRA-ORPHAN MEDICINE WITH PAS</b>  <b>This was noted.</b></li> <li>• pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda) (MCC) Merck Sharp &amp; Dohme (UK) Limited SMC2501 <b>ACCEPTED RESTRICTED WITH PAS</b>  <b>This was noted and the West of Scotland Cancer Network (WoSCAN) will provide guidance.</b></li> <li>• nivolumab 10mg/mL concentrate for solution for infusion (Opdivo) (MIUC) Bristol Myers Squibb Pharmaceuticals Ltd SMC2503 <b>ACCEPTED WITH PAS</b>  <b>This was noted and the West of Scotland Cancer Network will provide guidance.</b></li> </ul> <p><b><u>ABBREVIATED SUBMISSIONS</u></b></p> <ul style="list-style-type: none"> <li>• upadacitinib 15mg prolonged-release tablets (Rinvoq) (nr-axSpA) AbbVie Ltd SMC2532 <b>ACCEPTED WITH PAS</b>  <b>This was noted and will be referred to Rheumatology for comment.</b></li> <li>• eptinezumab 100mg concentrate for solution for infusion (Vyepti) Lundbeck Ltd SMC2547 <b>ACCEPTED RESTRICTED WITH PAS-</b>  <b>This was noted and will be referred to Neurology for comment.</b></li> </ul> <p><b><u>AMENDED ADVICE</u></b></p> <ul style="list-style-type: none"> <li>• mocertinib 40mg hard capsules (Exkivity®) Takeda UK Ltd SMC2516-  <b>This was noted and the West of Scotland Cancer Network will provide guidance.</b></li> <li>• tepotinib 225mg film-coated tablets (Tepmetko®) Merck Serono Ltd SMC2535<b>This was noted and the West of Scotland Cancer Network will provide guidance.</b></li> <li>• ferric maltol 30mg hard capsules (Feraccru®) Norgine Pharmaceuticals Ltd SMC2500-is <b>not recommended for use within NHSScotland.</b></li> </ul>	

	<p><b>This was noted.</b></p> <p><b><u>Paediatric Licence Extensions</u></b></p> <p>For noting. These will be shared with paediatrics for information</p>	<b>CM</b>
2023/05	<p><b>5. <u>SMC follow up</u></b></p> <p>CM talked the Committee through the SMC follow up which had been previously circulated.</p> <p>The committee also discussed the need to ensure all items have a decision. It was suggested that a final communication would be helpful to remind clinicians that a specific product will automatically be designated <i>“Not routinely available as there is a local preference for alternative medicines”</i> if no further communication is received</p>	
2023/06	<p><b>6. <u>Lanarkshire Formulary</u></b></p> <p>CM presented three formulary amendments.</p> <p>The first was to add a link to national guidance to adalimumab, infliximab and etanercept for rheumatoid arthritis.</p> <p>The second was the addition of Trimbaw® 172mcg/5mcg/9mcg to the formulary for asthma, following ratification of the clinical protocol referred to above.</p> <p>The third was an update to the ‘Drugs Used in the Treatment of Obesity’ section following recent ratification of the NHS Lanarkshire guideline ‘Liraglutide (Saxenda®) as an Adjunct to Lifestyle Measures in Weight Management.’</p> <p>The Committee ratified the proposed amendments.</p>	
2023/07	<p><b>7. <u>Clinical Protocols</u></b></p> <p><b>(a) <u>Roxadustat</u></b></p> <p>Section 5 not complete. To be discussed with author VG to follow up</p> <p><b>(b) <u>Upadacitinib for Rheumatoid Arthritis</u></b></p> <p>Protocol agreed, other than some minor corrections-</p> <ul style="list-style-type: none"> <li>• Needs ® added where brand name is used</li> <li>• Small typo in service implication section-“additonal” to be corrected</li> <li>• Formatting- eligibility criteria has one of the exclusion criteria items in that box</li> </ul> <p>It was discussed that the pathway for RA may need updated</p>	<p><b>VG</b></p> <p><b>VG</b></p>

	<p>(c) <b><u>Belimumab for SLE</u></b>  Both documents agreed in principal.  Formatting-eligibility criteria  Question raised about when sc versus iv would be used  VG to check with author as it may be helpful to add this detail to the protocol</p>	VG
2023/08 8.	<p><b><u>ADTC New Medicines Decisions</u></b></p> <p>The December 2022 New Medicines Decisions were noted.  The August 2022 New Medicines Decisions were updated to reflect local advice for SMC2334 Trimbow®.  The December 2021 New Medicines Decisions were updated to reflect WoSCAN advice for SMC2368 olaparib (Lynparza®) .  The June 2022 New Medicines Decisions were updated to reflect WoSCAN advice for SMC2476 lenvatinib (Kispplx®).  The March 2022 New Medicines Decisions were updated to reflect WoSCAN advice for SMC2404 dostarlimab (Jemperli®).  The May 2022 New Medicines Decisions were updated to reflect local advice for SMC2344 liraglutide (Saxenda®).</p>	
2023/09 9.	<p><b><u>Unlicensed Medicines</u></b></p> <p>nil</p>	
2023/10 10.	<p><b><u>Patient Group Directions</u></b></p> <p>(a) Ophthalmology PGD's- would be reviewed in line with pre-existing process with a view of approval</p> <p>The group agreed that there was a pre-existing process of PGD authorisation in place that secured appropriate scrutiny and approval. It was agreed that PGDs no longer need to be reviewed at ADTC. The group agreed this can be removed as a standing item.</p>	
2023/11 11.	<p><b><u>Medication and Clinical risk in Lanarkshire</u></b>  <a href="https://www.gov.uk/drug-safety-update">https://www.gov.uk/drug-safety-update</a></p> <p>Nil</p>	
2023/12 12.	<p><b><u>Regional Cancer Advisory Network</u></b>  <b><u>Check recording around 11:00</u></b></p> <p>Mr Milne gave an overview of the individual protocols as well as the governance structures in which they are developed and approved.  CM to update the relevant bulletins.</p>	

2023/13 13.	<p><b><u>Patient Safety Alerts</u></b></p> <p>Nil</p>	
2023/14 14.	<p><b><u>Lay member related items</u></b></p> <p>Nil</p>	
2023/15 15.	<p><b><u>Correspondence</u></b></p> <p>(i) <b><u>(ADTC) Collaborative -Framework for the supply of Naloxone within Scottish Prisons</u></b>  Refer to Duncan Hill and Jacqueline Kelland to review and feedback to ADTC that the actions recommended in the document are complete.  Comment was made about the specific mention of Lloyds Pharmacy in a national document. CG to feedback this comment to ADTCC</p> <p>(ii) <b><u>SAPG –OPAT Good Practice Guide</u></b>  SD summarised the document.  There are some off-label recommendations noted, however these have either been reviewed and agreed previously or reflect current practice, both locally and internationally. It is unlikely that the manufacturers will apply for licenses for these so the group were comfortable to approve the document.</p>	<b>VG/CG</b>
2023/16 16.	<p><b><u>Pharmacy &amp; NMAHP Prescribing Governance</u></b></p> <p>Nil noted</p>	
2023/17 17.	<p><b><u>AOCB</u></b></p> <p>a. MK gave update about availability of Clinical portal for GP's. Clinical portal is readily available to GPs form IT point of view but access is voluntary, and dependent on individual preferences.</p>	
2023/18 18.	<p><b><u>Date of next meeting</u></b></p> <p>15<sup>th</sup> February 2023 @ Microsoft Teams 10am</p>	